Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04293042 · ClinicalTrials.gov registry record · Early Phase 1

Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients

A Early Phase 1 study of BK Polyomavirus, sponsored by Children's Hospital of Philadelphia.

Recruiting
Registry status
Early Phase 1
Development phase
20
Enrollment target
1
Study location

NCT04293042 is a Early Phase 1 study of BK Polyomavirus that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04293042, a Early Phase 1 study of BK Polyomavirus, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.

RECRUITING
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT), renal transplantation, and chemotherapy.

Conditions Studied

Interventions

  • BIOLOGICAL BK-virus specific CTLs

Study Locations (1)

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2019-10-07
Est. Completion 2028-12-30
Phase Early Phase 1

Sponsor

Children's Hospital of Philadelphia

431 total trials

What the Registry Record Tells You About NCT04293042

The ClinicalTrials.gov registry entry for NCT04293042 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with BK Polyomavirus appearing as the primary indexed condition, and to 1 intervention - of which BK-virus specific CTLs is the first listed.

NCT04293042 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04293042 about?

NCT04293042 is a clinical study titled "Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients". This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantat...

What is the current status of trial NCT04293042?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2019-10-07. Estimated completion is 2028-12-30.

What conditions does trial NCT04293042 study?

This clinical trial studies the following conditions: BK Polyomavirus.

What interventions are being tested in trial NCT04293042?

The interventions under investigation include: BK-virus specific CTLs (BIOLOGICAL).

Who is sponsoring clinical trial NCT04293042?

This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04293042 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.